title: Tadalafil as treatment for idiopathic pulmonary arterial hypertension.
abstract: Phosphodiesterase inhibitors like sildenafil have already been shown to improve functional capacity and hemodynamics in the treatment of pulmonary arterial hypertension. Few studies address the effects of new phosphodiesterase inhibitors as tadalafil. We report a case of a patient with idiopathic pulmonary arterial hypertension in functional class IV (New York Heart Association) with significant response to treatment with tadalafil.
authors: Grupo de Hipertensão Pulmonar, Instituto do Coração do Hospital das Clínicas, FM, USP, São Paulo, SP, Brazil.
authors: Adriana Castro
authors: AC
authors: de Carvalho
authors: André Luiz
authors: AL
authors: Hovnanian
authors: Caio Julio César dos Santos
authors: CJ
authors: Fernandes
authors: Mônica
authors: M
authors: Lapa
authors: Carlos
authors: C
authors: Jardim
authors: Rogério
authors: R
authors: Souza
mesh_terms: D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000328:Adult; D002243:Carbolines / Q000627:therapeutic use*; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D012720:Severity of Illness Index; D000068581:Tadalafil
chemical_list: D002243:Carbolines; D010726:Phosphodiesterase Inhibitors; D000068581:Tadalafil; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human